Viva Biotech Awarded 'Top 10 Public Companies'

BEIJING, Dec. 24, 2019 /PRNewswire/ -- The 'Future Healthcare VB 100 Summit' organized by VCBeat and VCBeat Research was held in Beijing. Viva Biotech was invited to the Summit and awarded the 'Top 10 Public Companies 2019' with honor.

Dr. David Xu, the Chief Business Officer of Viva Biotech, was invited to deliver a keynote speech themed 'Early-stage Investment of Innovative Drugs: Valuation and Orientation'. In the speech, he shared views of the current situation of innovative drugs early-stage investments and introduced Viva Biotech's EFS business model. Through investment, incubation and R&D cooperation, Viva BioInnovator provides initial boost to promising start-ups' transition from 0 to 1. From Dr. Xu's perspective, instead of focusing on first-in-class or best-in-class drugs, the value judgement of such investments should depend on the drug's market demands and technological breakthroughs.

Dr. Xu said, "The innovations and investments of biopharmaceutics in China are currently facing the best timing and environment, with enormous unmet demands against cancer, neurodegeneration, immune diseases, etc. Breakthroughs in technologies will accelerate individual treatment process, and the comprehensive system and technologies will expedite drug discoveries with higher efficiency and lower costs." As he mentioned, Viva BioInnovator will continue exploring biotechnology start-ups with high potential worldwide, proactively fostering and participating in establishing a bio-medical ecosystem as well as assisting entrepreneurs with the transition from concepts to start-ups to pharmaceutical enterprises.

VCBeat and its subsidiary VCBeat Research founded the 'Future Healthcare VB 100 List' in 2015, aiming to select domestic core strength in future healthcare industry and boost the evolution of the innovative healthcare field. VCBeat proactively selected innovative domestic enterprises standing for the industry's future and announced in the Summit the 'Top 10 Public Companies'. Shortlisted as one of the 'Top 10 Public Companies', Viva Biotech has gained abundant recognition from the market for its strength in R&D service and innovative business model.

About Viva Biotech Holdings

Viva Biotech's mission is to become a cradle for innovative biotechnology companies around the world. Viva Biotech has developed a scalable business model combing the conventional cash-for-service (CFS) model and its unique equity-for-service (EFS) model. Under the CFS model, the Group provides structure-based drug discovery services to its biotechnology and pharmaceutical customers worldwide for their pre-clinical stage innovative drug development, covering the full spectrum of the customers' needs for early stage drug discovery, including target protein expression and structure research, hit screening, lead optimization and drug candidate determination. Viva Biotech also provides drug discovery and incubation services to biotechnology start-up companies with high potential under its EFS model. As of June 30, 2019, Viva Biotech had provided drug discovery services to 388 biotechnology and pharmaceutical customers worldwide, worked on over 1,000 independent drug targets, delivered over 11,000 independent protein structures, and incubated a total of 37 early stage R&D projects.

SOURCE Viva Biotech Holdings